SEARCH

News » National

Updated: April 2, 2013 01:12 IST

We will not yield to pressure to grant patents, says Sharma

Sujay Mehdudia
Comment   ·   print   ·   T  T  
Anand Sharma
Anand Sharma

Union Commerce and Industry Minister Anand Sharma has termed “historic” the Supreme Court’s rejection of Novartis’ claim for patent for its anti-cancer drug Glivec.

He said the Indian Patent Act was in conformity with its international obligations under the Trade Related Aspects of Intellectual Property Rights Agreement. “It is a historic judgment. It reaffirms the position of Indian law and, in particular, provisions of Section 3D, which mandates… a substantive innovation… for grant of a fresh patent,” he said in a statement here.

Along with his Ministry, Mr. Sharma has been a strong votary of a compulsory licensing regime and has favoured no-compromise approach to the issue of life-saving drugs. “We have a commitment to the people of India, especially the poor, and will not succumb to any kind of pressure to grant patents beyond their normal lives….”

Novartis does not have a patent for Glivec in the Indian market as the drug was introduced here before India adopted its new patent regime.

However, since the new version of the drug is just a small improvement on the older one, India has rejected the company’s patent appli cation.

This article is closed for comments.
Please Email the Editor

In the 16th Lok Sabha Election 2014, West Bengal has witnessed some interesting trends. Apart from the debacle of the Left and the ascendance of the Trinamool Congress (AITC), the other somewhat s... »

International

Tamil Nadu

Andhra Pradesh

Karnataka

Kerala


O
P
E
N

close

Recent Article in National

World Cup 2014 draws 20% more fans from India

The Brazilian Embassy has issued a record number of visas, free of cost, for World Cup goers »